Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infezioni da virus respiratorio sinciziale - vaccini - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. vedi sezioni 4. 2 e 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.